Fractional Flow Reserve, Coronary Flow Reserve and the Index of Microvascular Resistance in Clinical Practice

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare:

For permissions and non-commercial reprint enquiries, please visit to start a request.

For author reprints, please email
Average (ratings)
No ratings
Your rating



Citation:, February 2014

Support:The publication of this information was supported by St. Jude Medical.

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Information on coronary physiology is increasingly important to inform treatment decisions in the cardiac catheter laboratory. The purpose of this article is to review the rationale and indications for fractional flow reserve (FFR), coronary flow reserve (CFR) and the index of microvascular resistance (IMR) in interventional cardiology practice. A second objective is to highlight strengths and limitations of FFR, CFR and IMR, and discuss their value in clinical practice.

The Public Health Burden of Coronary Heart Disease
Coronary heart disease is the major cause of premature morbidity and death globally.1–3 In developed countries, chest pain accounts for at least 1% of all visits to a general practitioner,4,5 5% of all emergency department visits and 40% of emergency admissions to hospitals.6 Angina pectoris, derived from the Latin verb angere and first described by William Heberden in 1772, is chest pain of cardiac origin. The pathophysiology of angina involves a relative deficiency of myocardial oxygen supply (i.e. ischaemia) and typically occurs after physical activity and stress. Angina is usually secondary to obstructive coronary artery disease (CAD), but it may also occur in the absence of a flow-limiting stenosis (i.e. microvascular angina).7–12 This condition is prognostically important.13,14 Another possible cause of angina involves a combination of epicardial and small vessel CAD, which together contribute to ischaemic symptoms. This pathophysiology may explain why angina persists and drug therapy is still needed in some patients even after successful percutaneous coronary intervention (PCI).

Diagnosis of Angina in the Catheter Laboratory
European clinical guidelines now recommend that symptomatic patients with a high likelihood of angina (e.g. 60–90% likelihood) should be referred directly for invasive coronary angiography without prior stress testing.1,2 Other patients with suspected angina and a lower likelihood of ischaemia should follow non-invasive diagnostic pathways.1,2 The current North American guidelines provide a qualified recommendation of an initial invasive diagnostic strategy with coronary angiography,3 with invasive coronary angiography otherwise recommended following stress-testing. The European guidelines support a more direct, optimised approach to the management of symptomatic coronary disease. Skipping the non-invasive pathway and proceeding directly to invasive angiography means that patients who are most likely to have obstructive coronary disease will be managed more efficiently in terms of time and resources.

Limitations of Angiography-based Treatment Decisions
A coronary angiogram provides an anatomical assessment of the presence and extent of coronary disease severity. Treatment decisions, which include medical therapy, PCI or coronary artery bypass surgery (CABG),15 are based on a visual interpretation of the coronary angiogram. Occasionally, treatment decisions are deferred in order to obtain further diagnostic information. However, visual interpretation of the coronary angiogram may be inaccurate, and clinical judgments made by individual cardiologists in everyday practice are subjective, potentially leading to misdiagnosis and incorrect treatment decisions.16,17

Making treatment decisions for patients with multiple coronary narrowings based on angiographic findings is particularly challenging since identifying the culprit stenosis (or stenoses) and discriminating flow-limiting from non-culprit flow disease is subjective and potentially unreliable.15–18 Since treatment decisions have prognostic importance and resource implications, misinterpretation of an angiogram could lead to inappropriate decisions, sub-optimal health outcomes16–18 and significant future healthcare costs.

Fractional Flow Reserve Measurement in the Catheter Laboratory – Clinical Utility
Diagnostic methods for assessing coronary artery function have rapidly evolved in recent years. Guidewire-based measurement of coronary blood pressure, temperature and resistance now provide new diagnostic possibilities. Seminal work by Gould and colleagues19–21 and by De Bruyne and Pijls22 facilitated by technological advantages provided by coronary guidewire sensor technology now mean that cardiologists can measure lesion-level ischaemia, coronary collateral supply and other parameters of microvascular function.23,24 The indications for FFR, CFR and IMR are summarised in Table 1.

Table 1: Clinical Circumstances Where Fractional Flow Reserve, Pressure-derived Collateral Flow Index, Coronary Flow Reserve and Index of Microvascular Resistance May Have Diagnostic and Clinical Utility
Clinical Circumstances Where Fractional Flow Reserve
Fractional Flow Reserve for the Diagnosis of Flow-limiting Coronary Artery Disease
Coronary stenosis severity and lesion-level ischaemia can be assessed invasively based on the myocardial fractional flow reserve (FFR = resting distal coronary pressure to aortic pressure ratio [Pd/Pa] during hyperaemia and the ischaemic threshold ≤0.80)22,31,32 (see Figure 1). When coronary resistance is minimised, flow becomes linearly related to blood pressure in the physiological range. Thus, FFR is a surrogate measure of flow limitation and lesion-level ischaemia. Recent studies (Deferral versus Performance of PTCA in Patients without Documented Ischemia [DEFER],31 Fractional Flow Reserve versus Angiography for Multivessel Evaluation [FAME]32 and FFR-Guided Percutaneous Coronary Intervention plus Optimal Medical Therapy versus Medical Therapy Alone in Patients with Stable Coronary Artery Disease [FAME 2]33) in patients with stable CAD have put forward a new evidence-based approach to diagnostic decisions. FFR ≤0.80 derived from the pressure guidewire is an evidence-based physiological threshold indicative of obstructive coronary disease that could benefit from revascularisation. Alternatively, FFR >0.80 implies that medical therapy rather than revascularisation is indicated32,33 (see Figure 2).

Figure 1: Myocardial Fractional Flow Reserve – Fractional Flow Reserve = Pd/Pa During Hyperaemia
Myocardial FFR – FFR = Pd/Pa During Hyperaemia
Figure 2: Diagnosis and Treatment Based on Fractional Flow Reserve and Coronary Flow Reserve Values
Diagnosis and Treatment Based on, Fractional and Coronary Flow Reserve Values
The diagnostic categorisations and treatment recommendations are provided as an indicative guide. Clinicians should follow clinical guidelines1,3,15 in clinical practice. IMR is not included in this figure since more information is needed to establish cut-off values for microvascular dysfunction.

The DEFER,31 FAME32 and FAME 233 studies demonstrated the benefits of using FFR measurement to more accurately identify stenoses that are flow-limiting and guide PCI with resulting improved outcomes and reduced costs34 compared with angiography alone. FFR measurement can identify and exclude obstructive CAD with high diagnostic accuracy,22,35 even in patients with prior myocardial infarction (MI).36

The FAME trial32 found marked discordance between angiographic and FFR assessment of stenosis severity with a general over-estimation of disease severity with angiography.35

Clinical guidelines conclude that when non-invasive diagnostic stress test information is not available, FFR is helpful15 and that FFR is indicated for moderate coronary stenoses (e.g. 50–90%) when functional information is lacking15 (see Table 1). In the UK, the British Cardiovascular Intervention Society has recognised the clinical importance of FFR. Measuring FFR is considered an Interventional Diagnostic Procedure37 relevant for reimbursement

Fractional Flow Reserve and Microvascular Angina
Microvascular angina is defined as the occurrence of typical angina symptoms that respond to anti-angina therapies in patients without obstructive CAD.7–12 Ischaemic chest pain in patients without obstructive CAD can be classified as Type 1, microvascular angina1,9,10 (see Figure 2). Recent guidelines from the European Society of Cardiology1 have placed renewed emphasis on microvascular angina as a clinical and public health problem, and studies have found that microvascular angina has prognostic importance.13,14

Myocardial perfusion is regulated by arterioles (10–200 m diameter) within the muscle and epicardium (pre-arterioles, 200–500 m). These small blood vessels contribute about 50% and 25% to total coronary vascular resistance, respectively.8 The pathophysiology of coronary microvascular disease involves a reduction in the number of microvascular arterioles and potential microvascular hypertrophy. The number of microvascular capillaries correlates inversely with symptoms. Coronary microvascular abnormalities are classically associated with hypertension,38,39 but may also occur in atherosclerotic coronary disease.40 Vasodilator capacity is measured by stress testing or CFR.19,40,41

Historically, limitations in testing methods have made it difficult to diagnose microvascular disease. A coronary angiogram is the reference test for the diagnosis of CAD.15 However, the imaging information is essentially anatomical whereas diagnostic information on microvascular disease requires a functional test.1,2,20

From a practical perspective, FFR can be used to rule-out lesion-level ischaemia in patients with mild or intermediate CAD (see Table 1). In this case, microvascular angina may be the final diagnosis if symptoms, response to drug therapy and non-invasive tests are indicative of ischaemia. Since the PressureWire™ Certus™ guidewire can measure microvascular function as well as FFR, microvascular angina can now be assessed in the catheter laboratory (see Table 1).

Catheter Laboratory Measurements – Practical Considerations
Fractional Flow Reserve
Clinical guidelines recommend FFR measurements for lesions with a stenosis severity of 50–90%15 (see Table 1). A 0.014” coronary PressureWire guidewire (e.g. PressureWire Certus or PressureWire Aeris™ guidewire) should be used for making FFR measurements. More detailed information on the clinical circumstances for FFR and guidance on measurement can be found in Table 1. FFR also has prognostic value for assessing the final results of PCI. Pijls et al.42 have shown that a FFR >0.95 is associated with a lower rate of adverse outcomes that are more likely to occur with post-PCI FFR values <0.95. Expert review articles have provided guidance on the practical considerations for FFR measurement.24,43

Fractional Flow Reserve in Routine Practice
FFR is straightforward to acquire and with training and experience should only add a few minutes to the diagnostic procedure. However, optimal data acquisition and interpretation require a good understanding of the methodology. FFR values are influenced by practical considerations and patient-level and coronary factors. Practical considerations for FFR measurement based on the author’s clinical practice and experience are listed in Table 2. Patient-level factors relevant to FFR measurement include obtaining a haemodynamic response to adenosine. The coronary artery characteristics relevant to FFR measurement include left main (LM) disease, chronic total occlusion (CTO), tandem lesions and acute coronary syndromes (ACS).

Table 2: Tips and Tricks for Optimal Measurement of Fractional Flow Reserve
Tips and Tricks for Optimal Measurement of Fractional Flow Reserve
Fractional Flow Reserve in Selected Circumstances
Given the prognostic significance of the LM coronary artery, treatment decisions for revascularisation or medical therapy alone are particularly important. In a cohort study of 213 patients with angiographically equivocal LM disease, Hamilos et al.44 found that the prognosis of patients managed medically based on FFR >0.80 was similar to that of patients with FFR ≤0.80 who underwent CABG. This result indicates that FFR-guided treatment decisions in patients with equivocal LM disease are associated with favourable outcomes. In patients with downstream disease, FFR is only affected if the stenosis in the branch artery is proximal and very severe.45

In CTOs, a FFR value in a collateral donor artery will be lower than would be the case if there were no collateral connections. After PCI and restoration of flow, the FFR in the collateral donor artery will rise. Therefore, where clinically appropriate, PCI should be performed first in the recipient artery. Then FFR may be more reliably evaluated in lesions in the collateral donor artery. In tandem lesions, a pull-back recording during hyperaemia should be performed in order to determine whether one or more of the lesions is making a functionally important contribution to the FFR value. This would be revealed as a step-up in the FFR value >0.80 as the wire is pulled back across the stenosis of interest.43 PCI should be performed in the most severe lesion first and then FFR can be re-assessed afterward.

Several factors may influence the validity of FFR in ACS patients. If MI has occurred, the patient’s microcirculation may be severely injured and theoretically may compromise the response to adenosine. Thus, acute measurement of FFR in the culprit coronary artery during primary PCI is not recommended. However, FFR measurement in non-culprit lesions remains valid and is indeed the subject of current research.46 A detailed discussion of these subjects is beyond the scope of this review, and references are mentioned for further reading.

Resting Pressure Indices
The relationship between the distal and proximal coronary (aortic) pressures is influenced by stenosis severity both throughout the cardiac cycle or when restricted to diastole. However, the relationships between a resting pressure index and FFR are closest at the extremes of the range (the coefficient of determination [R2] is >0.9 for mild and severe stenosis). In the clinically important range for treatment decisions (i.e. FFR between 0.60 and 0.90), the diagnostic accuracy for lesion-level ischaemia revealed by FFR ≤0.80 is moderate at best.47 The diagnostic accuracy of a hybrid approach and safety of treatment decisions based on a hybrid approach are unknown.

Coronary Wedge Pressure and Fractional Coronary Collateral Supply
Coronary collateral connections represent a nascent or adaptive response to ischaemia and alterations in hydrostatic pressure.25 For example, when antegrade flow is interrupted, such as during coronary balloon inflation, the pressure measured in the distal vessel beyond the occlusion (i.e. wedge pressure [Pw]) reflects the collateral coronary supply.25,43 The pressure-derived fractional coronary collateral flow index takes the venous pressure into account and can be calculated according to the following equation:

CFIp = (Pw – Pv) / (Pa – Pv)
(Pv is venous pressure ideally measured from the right atrium and Pa is the aortic pressure measured from the guide catheter.)

Coronary wedge pressure is typically 0.1– 0.3 in humans, and values >0.20 indicate an adequate collateral supply that may limit infarct size in acute MI.25 The wedge pressure, therefore, provides an indication of the coronary collateral supply in patients with stable and acute coronary disease.

Coronary Flow Reserve
Since coronary flow and resistance are inversely related, microvascular function can be measured by integrating pressure and temperature measured simultaneously using thermodilution-based measurements of coronary artery flow and pressure. These measurements, which can be made using a pressure- and temperature-sensitive coronary guidewire,26 provide information about coronary vascular function (see Table 1).

CFR represents the vasodilator capacity of the coronary vascular bed during hyperaemia and is measured by indicator thermodilution (see Table 3). A bolus of saline (i.e. 3 mL) at room temperature injected through the guide catheter will mix with antegrade coronary blood flow at body temperature, causing a transient reduction in temperature that is measured by the thermistor, located 3 cm from the distal end of the guidewire. The thermodilution curve is reflected by a transit time. Accepting the variability that may occur with this type of measurement, the mean transit time for three saline injections is displayed at rest and during pharmacological hyperaemia.26

Table 3: Key Steps for Thermodilution Measurements
Key Steps for Thermodilution Measurements
Index of Microvascular Resistance
Myocardial resistance is mainly determined by the microcirculation. IMR is a coronary guidewire-based measure of coronary microvascular function48,49 (see Table 1). IMR provides information on microvascular dysfunction that could be informative both in stable patients and also in patients with acute or recent MI (see Table 1). Compared with FFR, less information is known about IMR, and it is not known whether therapeutic reduction of IMR (e.g. with an intracoronary vasodilator) confers clinical benefits. Nor is it known whether treatment decisions based on an IMR threshold might have prognostic benefits (as has been shown to be the case with FFR.

In a simplified form, assuming coronary flow and myocardial flow are equal and that the contribution of collateral flow is negligible, then:

IMR = distal coronary pressure / coronary flow
IMR can be used to study the pathophysiology of microvascular function in patients with stable symptoms27,50,51 and in acute MI28,29,51 where it has prognostic importance.30 An IMR <20 is in the normal range, and an IMR >30 is elevated (i.e. microvascular dysfunction in acute or stable coronary disease) (see Figure 3). IMR at the end of PCI is higher in patients who have subsequent evidence of procedure-related MI.50

Figure 3: Measurement of the Index of Microvascular Resistance
Measurement of the Index of Microvascular Resistance
The apparent IMR is calculated by multiplying the distal coronary pressure by the mean transit time of a 3 ml bolus of saline at room temperature during coronary hyperaemia induced by intravenous adenosine49 (see Table 3). Pressure and temperature are measured simultaneously since the pressure-sensor and thermistor are located at the same point on the coronary guidewire (3 cm from the distal end). IMR may be expressed as mmHg x s, or it can be reported in units since it is an index. The mean distal coronary pressures must be recorded during maximal hyperaemia. Previous studies in patients with stable coronary disease have established that IMR measurement is repeatable and independent of haemodynamic variations, including heart rate, blood pressure and myocardial contractility.53

Since a coronary stenosis may be associated with a recruitable collateral supply, the coronary wedge pressure and venous pressure should be used to estimate IMR when IMR is measured in an obstructed coronary artery,54 according to the following equation:

IMRc = [(Pa – Pv) x Tmn] x [(Pd – Pw) / (Pa – Pw)]
When wedge and venous pressure are not available, IMR may be estimated using this equation:52

IMR = Pa x Tmn x FFRcor


FFRcor = 1.34 x FFRmyo - 0.32

IMR is straightforward to measure and takes just a few minutes. From a practical point of view, it is important to ensure that the guide catheter is flushed with saline before each injection since armed saline within the guide could contribute to variations in the thermodilution curves. It is also essential to eradicate air bubbles from the tubing and guide catheter.

We recommend performing the thermodilution test initially during resting conditions and then following induction of hyperaemia with intravenous adenosine. The resting measurement provides the basal resistance index. Following induction of hyperaemia, one would expect to observe a left shift in the transit times, indicating an increase in coronary flow velocity due to minimisation of coronary resistance. The resistance reserve ratio (RRR) is the ratio of basal resistance / IMR. Emerging data suggest this ratio has discriminatory value in patients with stable and unstable coronary disease.51

While the limitations of angiography-based treatment decisions regarding revascularisation have been well documented, diagnostic methods for assessing coronary artery function have evolved rapidly in recent years. Moreover, it is now possible to assess FFR, CFR and IMR conveniently in the catheter laboratory with a coronary pressure guidewire. Of these assessment tools, FFR has become increasingly important for decision-making as evidenced by significant clinical trials, including DEFER, FAME and FAME 2.

On the other hand, CFR and IMR can serve as complementary tools by providing extensive information about epicardial and microvasculature resistance. In the future, haemodynamic coronary assessment tools will become more sophisticated resulting in better assessment of CAD and its treatment.


  1. Montalescot G, Sechtem U, Achenbach S, et al., 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary disease of the European Society, Eur Heart J, 2013;34(38):2949–3003.
  2. Cooper A, Calvert N, Skinner J, et al., Chest pain of recent onset: Assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin, London, UK: National Clinical Guideline Centre for Acute and Chronic Conditions, 2010:35.
  3. Fihn SD, Gardin JM, Abrams J, et al., 2012 ACCF/AHA/ ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons, Circulation, 2012;126(25):e354–471.
  4. Ruigómez A, Rodriguez LA, Wallander MA, et al., Chest pain in general practice: incidence, comorbidity and mortality, Fam Pract, 2006;23(2):167–74.
  5. Nilsson S, Scheike M, Engblom D, et al., Chest pain and ischaemic heart disease in primary care, Br J Gen Pract, 2003;53(490):378–82.
  6. Murphy NF, MacIntyre K, Capewell S, et al., Hospital discharge rates for suspected acute coronary syndromes between 1990 and 2000: population based analysis, BMJ, 2004;328(7453):1413–4.
  7. Marzilli M, Merz CN, Boden WE, et al., Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link!, J Am Coll Cardiol, 2012;60(11):951–6.
  8. Kaul S, Jayaweera AR, Myocardial capillaries and coronary flow reserve, J Am Coll Cardiol, 2008;52(17):1399–401.
  9. Camici PG, Crea F, Coronary microvascular dysfunction, N Engl J Med, 2007;356(8):830–40.
  10. Herrmann J, Kaski JC, Lerman A, Coronary microvascular dysfunction in the clinical setting: From mystery to reality, Eur Heart J, 2012;33(22):2771–82b.
  11. Yilmaz A, Sechtem U, Angina pectoris in patients with normal coronary angiograms: current pathophysiological concepts and therapeutic options, Heart, 2012;98(13):1020–9.
  12. Sharaf BL, Pepine CJ, Kerensky RA, et al., Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory), Am J Cardiol, 2001;87(8):937–41; A3.
  13. Johnson BD, Shaw LJ, Buchthal SD, et al., Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute- Sponsored Women’s Ischemia Syndrome Evaluation (WISE), Circulation, 2004;109(24):2993–9.
  14. Suwaidi JA, Hamasaki S, Higano ST, et al., Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction, Circulation, 2000;101(9):948–54.
  15. Wijns W, Kolh P, Danchin N, et al., Guidelines on myocardial revascularization, Eur Heart J, 2010;31(20):2501–55.
  16. Selby JV, Fireman BH, Lundstrom RJ, et al., Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization, N Engl J Med, 1996;335(25):1888–96.
  17. White CW, Wright CB, Doty DB, et al., Does visual interpretation of the coronary arteriogram predicts the physiologic importance of a coronary stenosis?, N Engl J Med, 1984;310(13):819–24.
  18. Carrick D, Behan M, Foo F, et al., Usefulness of fractional flow reserve to improve diagnostic efficiency in patients with non-ST elevation myocardial infarction, Am J Cardiol, 2013;111(1):45–50.
  19. Gould KL, Lipscomb K, Hamilton GW, Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve, Am J Cardiol, 1974;33(1):87–94.
  20. Gould KL, Lipscomb K, Effects of coronary stenoses on coronary flow reserve and resistance, Am J Cardiol, 1974;34(1):48–55.
  21. Gould KL, Pressure-flow characteristics of coronary stenoses in unsedated dogs at rest and during coronary vasodilation, Circ Res, 1978;43(2):242–53.
  22. Pijls NH, De Bruyne B, Peels K, et al., Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses, N Engl J Med, 1996;334(26):1703–8.
  23. Gould KL, Does coronary flow trump anatomy?, JACC Cardiovascular Imaging, 2009;2(8):1009–23. 24. Kern MJ, Samady H, Current concepts of integrated coronary physiology in the catheterization laboratory, J Am Coll Cardiol, 2010;55(3):173–85.
  24. Berry C, Balachandran KP, L’Allier PL, et al., Importance of collateral circulation in coronary heart disease, Eur Heart J, 2007;28(3):278–91.
  25. Barbato E, Aarnoudse W, Aengevaeren WR, et al., Validation of coronary flow reserve measurements by thermodilution in clinical practice, Eur Heart J, 2004;25(3):219–23.
  26. Melikian N, Vercauteren S, Fearon WF, et al., Quantitative assessment of coronary microvascular function in patients with and without epicardial atherosclerosis, EuroIntervention, 2010;5(8):939–45.
  27. McGeoch R, Watkins S, Berry C, et al., The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients with ST-segment elevation myocardial infarction, JACC Cardiovasc Interv, 2010;3(7):715–22.
  28. Payne AR, Berry C, Doolin O, et al., Microvascular Resistance Predicts Myocardial Salvage and Infarct Characteristics in ST-Elevation Myocardial Infarction, J Am Heart Assoc, 2012;1(4):e002246.
  29. Fearon WF, Low AF, Yong AS, et al., Prognostic value of the Index of Microcirculatory Resistance measured after primary percutaneous coronary intervention, Circulation, 2013;127(24):2436–41.
  30. Pijls NH, van Schaardenburgh P, Manoharan G, et al., Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study, J Am Coll Cardiol, 2007;49(21):2105–11.
  31. Tonino PA, de Bruyne B, Pijls NH, et al., Fractional flow reserve versus angiography for guiding percutaneous coronary intervention, N Engl J Med, 2009;360(3):213–24.
  32. De Bruyne B, Pijls NH, Kalesan B, et al., Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease, N Engl J Med, 2012;367(11):991–1001.
  33. Fearon WF, Bornschein B, Tonino PA, et al., Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease, Circulation, 2010;122(24):2545–50.
  34. Tonino PA, Fearon WF, De Bruyne B, et al., Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation, J Am Coll Cardiol, 2010;55(25):2816–21.
  35. De Bruyne B, Pijls NH, Bartunek J, et al., Fractional flow reserve in patients with prior myocardial infarction, Circulation, 2001;104(2):157–62.
  36. British Cardiovascular Intervention Society, PCI Dataset information, 2013. Available at: (Accessed 5 February 2014).
  37. Campbell DJ, Somaratn JB, Jenkins AJ, et al., Differences in myocardial structure and coronary microvasculature between men and women with coronary artery disease. Hypertension, 2011;57(2):186–92.
  38. Mundhenke M, Schwartzkopff B, Strauer BE, Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy, Virchows Arch, 1997;431(4):265–73.
  39. Escaned J, Flores A, García-Pavía P, et al., Assessment of microcirculatory remodeling with intracoronary flow velocity and pressure measurements: validation with endomyocardial sampling in cardiac allografts, Circulation, 2009;120(16):1561–8.
  40. Tsagalou EP, Anastasiou-Nana M, Agapitos E, et al., Depressed coronary flow reserve is associated with decreased myocardial capillary density in patients with heart failure due to idiopathic dilated cardiomyopathy, J Am Coll Cardiol, 2008;52(17):1391–8.
  41. Pijls NH, Klauss V, Siebert U, et al., Coronary pressure measurement after stenting predicts adverse events at follow-up: A multicenter registry, Circulation, 2002;105(25):2950–4.
  42. Pijls NH, Kern MJ, Yock PG, De Bruyne B, Practice and potential pitfalls of coronary pressure measurement, Catheter Cardiovasc Interv, 2000;49(1):1–16.
  43. Hamilos M, Muller O, Cuisset T, et al., Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis, Circulation, 2009;120(15):1505–12.
  44. Yong AS, Daniels D, De Bruyne B, et al., Fractional flow reserve assessment of left main stenosis in the presence of downstream coronary stenoses, Circ Cardiovasc Interv, 2013;6(2):161–5.
  45. Berry C, Layland J, Sood A, et al., Fractional flow reserve versus angiography in guiding management to optimise outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial, Am Heart J, 2013;166(4): 662–8.e3.
  46. Berry C, van ‘t Veer M, Witt N, et al., VERIFY (VERification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Coronary Artery Stenosis Severity in EverydaY Practice): a multicenter study in consecutive patients, J Am Coll Cardiol, 2013;61(13):1421–7.
  47. Aarnoudse W, van den Berg P, van de Vosse F, et al., Myocardial resistance assessed by guidewire-based pressure-temperature measurement: in vitro validation, Catheter Cardiovasc Interv, 2004;62(1):56–63.
  48. Fearon WF, Balsam LB, Farouque HM, et al., Novel index for invasively assessing the coronary microcirculation, Circulation, 2003;107(25):3129–32.
  49. Layland JJ, Whitbourn RJ, Burns AT, et al., The index of microvascular resistance identifies patients with periprocedural myocardial infarction in elective percutaneous coronary intervention, Heart, 2012;98(20):1492–7.
  50. Layland J, Carrick D, McEntegart M, et al., Vasodilatory capacity of the coronary microcirculation is preserved in selected patients with non-ST-segment-elevation myocardial infarction, Circ Cardiovasc Interv, 2013;6(3):231–6.
  51. Yong AS, Layland J, Fearon WF, et al., Calculation of the index of microcirculatory resistance without coronary wedge pressure measurement in the presence of epicardial stenosis, JACC Cardiovasc Interv, 2013;6(1):53–8.
  52. Yong AS, Ho M, Shah MG, et al., Coronary microcirculatory resistance is independent of epicardial stenosis, Circ Cardiovasc Interv, 2012;5(1):103–8, S1–2.
  53. Layland J, MacIsaac AI, Burns AT, et al., When collateral supply is accounted for epicardial stenosis does not increase microvascular resistance, Circ Cardiovasc Interv, 2012;5(1):97–102.